These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

761 related items for PubMed ID: 16243650

  • 21. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
    Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA.
    J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
    [Abstract] [Full Text] [Related]

  • 22. Preparation and characterization of a DOTA-lysine-biotin conjugate as an effector molecule for pretargeted radionuclide therapy.
    Hainsworth J, Harrison P, Mather SJ.
    Bioconjug Chem; 2005 Dec; 16(6):1468-74. PubMed ID: 16287243
    [Abstract] [Full Text] [Related]

  • 23. Improved in vivo stability and tumor targeting of bismuth-labeled antibody.
    Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M.
    Cancer Res; 1990 Jul 15; 50(14):4221-6. PubMed ID: 2364380
    [Abstract] [Full Text] [Related]

  • 24. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb 15; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis.
    McQuade P, Knight LC, Welch MJ.
    Bioconjug Chem; 2004 Feb 15; 15(5):988-96. PubMed ID: 15366951
    [Abstract] [Full Text] [Related]

  • 26. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
    Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM.
    Clin Cancer Res; 2000 Feb 15; 6(2):406-14. PubMed ID: 10690517
    [Abstract] [Full Text] [Related]

  • 27. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG, Oosterwijk E, Soede AC, Oyen WJ, McBride WJ, Griffiths GL, Goldenberg DM, Corstens FH, Boerman OC.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [Abstract] [Full Text] [Related]

  • 28. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.
    Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, Graves S, Bryan K, Reno JM.
    J Nucl Med; 2000 Jan 01; 41(1):131-40. PubMed ID: 10647616
    [Abstract] [Full Text] [Related]

  • 29. Pretargeted radioimmunotherapy.
    Meredith RF, Buchsbaum DJ.
    Int J Radiat Oncol Biol Phys; 2006 Jan 01; 66(2 Suppl):S57-9. PubMed ID: 16979441
    [Abstract] [Full Text] [Related]

  • 30. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
    Moosmayer D, Berndorff D, Chang CH, Sharkey RM, Rother A, Borkowski S, Rossi EA, McBride WJ, Cardillo TM, Goldenberg DM, Dinkelborg LM.
    Clin Cancer Res; 2006 Sep 15; 12(18):5587-95. PubMed ID: 17000696
    [Abstract] [Full Text] [Related]

  • 31. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG, Oosterwijk E, Soede AC, Broekema M, Frielink C, McBride WJ, Goldenberg DM, Corstens FH, Boerman OC.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [Abstract] [Full Text] [Related]

  • 32. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
    Almqvist Y, Steffen AC, Tolmachev V, Divgi CR, Sundin A.
    Nucl Med Biol; 2006 Nov 01; 33(8):991-8. PubMed ID: 17127172
    [Abstract] [Full Text] [Related]

  • 33. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
    Yao Z, Garmestani K, Wong KJ, Park LS, Dadachova E, Yordanov A, Waldmann TA, Eckelman WC, Paik CH, Carrasquillo JA.
    J Nucl Med; 2001 Oct 01; 42(10):1538-44. PubMed ID: 11585870
    [Abstract] [Full Text] [Related]

  • 34. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F, Horak EM, Garmestani K, Wu C, Brechbiel MW, Kozak RW, Tso J, Kosteiny SA, Gansow OA, Nelson DL.
    Cancer Res; 1994 Aug 15; 54(16):4362-70. PubMed ID: 8044783
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).
    Urbano N, Papi S, Ginanneschi M, De Santis R, Pace S, Lindstedt R, Ferrari L, Choi S, Paganelli G, Chinol M.
    Eur J Nucl Med Mol Imaging; 2007 Jan 15; 34(1):68-77. PubMed ID: 16755333
    [Abstract] [Full Text] [Related]

  • 36. Preclinical analysis of intraperitoneal administration of 111In-labeled human tumor reactive monoclonal IgM AC6C3-2B12.
    Quadri SM, Malik AB, Tang XZ, Patenia R, Freedman RS, Vriesendorp HM.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5736s-5742s. PubMed ID: 7493338
    [Abstract] [Full Text] [Related]

  • 37. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.
    Cheung NK, Modak S, Lin Y, Guo H, Zanzonico P, Chung J, Zuo Y, Sanderson J, Wilbert S, Theodore LJ, Axworthy DB, Larson SM.
    J Nucl Med; 2004 May 01; 45(5):867-77. PubMed ID: 15136638
    [Abstract] [Full Text] [Related]

  • 38. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.
    Zhang M, Yao Z, Garmestani K, Axworthy DB, Zhang Z, Mallett RW, Theodore LJ, Goldman CK, Brechbiel MW, Carrasquillo JA, Waldmann TA.
    Blood; 2002 Jul 01; 100(1):208-16. PubMed ID: 12070029
    [Abstract] [Full Text] [Related]

  • 39. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
    Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW.
    Blood; 2010 Nov 18; 116(20):4231-9. PubMed ID: 20702781
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
    Shankar S, Vaidyanathan G, Affleck DJ, Peixoto K, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2004 Oct 18; 31(7):909-19. PubMed ID: 15464393
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.